Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01235962 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

A Phase 3 study of Cancer and Renal Cell Carcinoma (RCC), sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
1,538
Enrollment target
20
Study locations

NCT01235962 is a Phase 3 study of Cancer and Renal Cell Carcinoma (RCC) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,538 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01235962, a Phase 3 study of Cancer and Renal Cell Carcinoma (RCC), has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
1,538 participants
Enrollment target
20
Study locations

Study Summary

This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

Conditions Studied

Cancer Renal Cell Carcinoma (RCC)

Interventions

  • DRUG placebo
  • DRUG pazopanib

Study Locations (20)

California

  • Novartis Investigative Site - Antioch
  • Novartis Investigative Site - Beverly Hills
  • Novartis Investigative Site - Fresno
  • Novartis Investigative Site - La Jolla
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Oakland
  • Novartis Investigative Site - Sacramento
  • Novartis Investigative Site - San Francisco
  • Novartis Investigative Site - South San Francisco
  • Novartis Investigative Site - Stanford
  • Novartis Investigative Site - Vallejo

Florida

  • Novartis Investigative Site - Fort Myers
  • Novartis Investigative Site - Tampa

Georgia

  • Novartis Investigative Site - Athens
  • Novartis Investigative Site - Macon

Arkansas

  • Novartis Investigative Site - Jonesboro

Colorado

  • Novartis Investigative Site - Fort Collins

District of Columbia

  • Novartis Investigative Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,538 participants
Start Date 2010-11-30
Est. Completion 2019-04-15
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01235962

The ClinicalTrials.gov registry entry for NCT01235962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,538 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (56% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01235962 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01235962 about?

NCT01235962 is a clinical study titled "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)". This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

What is the current status of trial NCT01235962?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2010-11-30. Estimated completion is 2019-04-15.

What conditions does trial NCT01235962 study?

This clinical trial studies the following conditions: Cancer, Renal Cell Carcinoma (RCC).

What interventions are being tested in trial NCT01235962?

The interventions under investigation include: placebo (DRUG), pazopanib (DRUG).

Who is sponsoring clinical trial NCT01235962?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01235962 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Renal Cell Carcinoma (RCC)

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.